Physician profile
Josephine Harrington
NPI 1720442569
$118,784.51
in general payments reported to CMS, 2019-2025
8 companies · $102K in 2025
The $102K reported for 2025 was more than what 98% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $17K · 2025: $102K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $101K · Travel and Lodging: $16K · Food and Beverage: $1,495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $100,903.50 |
| Travel and Lodging | $16,386.10 |
| Food and Beverage | $1,494.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $59,567.20 | 2024-2025 | |
| Novo Nordisk As | $28,301.44 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $24,528.78 | 2025 | |
| Eli Lilly and Company | $4,900.00 | 2025 | |
| Astrazeneca Ab | $1,134.00 | 2025 | |
| Cleerly, INC. | $155.89 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Amgen INC. | $149.73 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.47 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josephine Harrington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.